Management of chronic hepatitis C virus in patients with HIV

Current Treatment Options in Gastroenterology

Volumn 8, Issue 6, 2005, Pages 433-441

  Santos, Stephanie A ^b   Kontorinis, Nickolas ^b   Dieterich, Douglas T ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALPHA INTERFERON; ANTIDEPRESSANT AGENT; ANTIRETROVIRUS AGENT; CANNABINOID DERIVATIVE; DIDANOSINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRONABINOL; GRANULOCYTE COLONY STIMULATING FACTOR; LAMIVUDINE; MEDROXYPROGESTERONE ACETATE; METFORMIN; NEVIRAPINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PIOGLITAZONE; PLACEBO; PREDNISONE; PROTEINASE INHIBITOR; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; STAVUDINE; TENOFOVIR; UNINDEXED DRUG; WARFARIN; ZALCITABINE; ZIDOVUDINE;

ALOPECIA; ANEMIA; ANOREXIA; ANXIETY DISORDER; ARTHRALGIA; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONCENTRATION LOSS; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIARRHEA; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DRUG CLEARANCE; DRUG COST; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DYSPEPSIA; DYSPNEA; EOSINOPHILIA; EPIDEMIC; EYE DISEASE; FATIGUE; FATTY LIVER; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HEADACHE; HEALTH CARE DELIVERY; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; INSOMNIA; INSULIN RESISTANCE; KIDNEY FAILURE; LACTIC ACIDOSIS; LIFE EXPECTANCY; LIFESTYLE; LIPODYSTROPHY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FIBROSIS; LIVER TOXICITY; MENTAL DISEASE; MITOCHONDRIAL TOXICITY; MORBIDITY; MORTALITY; MYALGIA; NAUSEA; NEUTROPENIA; OPPORTUNISTIC INFECTION; PANCREATITIS; PARESTHESIA; PATIENT CARE; PRURITUS; PSYCHOSIS; RETINA ARTERY OCCLUSION; RETINA HEMORRHAGE; RETINA VEIN OCCLUSION; REVIEW; SKIN DISEASE; STANDARDIZATION; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUPERINFECTION; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VIRUS TRANSMISSION; VOMITING;

EID: 30344448552     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-005-0029-5     Document Type: Review

References (55)

1. Alter MJ, Kruszon-Moran D, Nainan OV, et al.: The prevalence of hepatitis C virus infection in the United States, 1988-1994. N Engl J Med 1999, 351:556-562.
2. Sherman KE, Rouster SD, Chung RT, Rajicic N: Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002, 34:831-837.
3. Sulkowski MS, Thomas DL: Hepatitis C in the HIV-Infected Person. Ann Intern Med 2003, 138:197-207.
4. Poynard T, Ratziu V, Charlotte F, et al.: Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001, 34:730-739.
5. Puoti M, Spinetti A, Ghezzi A, et al.: Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 2000, 24:211-217.
6. Bonacini M, Govindarajan S, Blatt LM, et al.: Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA. J Viral Hepat 1999, 6:203-208.
7. Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ: Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood 1994, 84:1020-1023.
8. Benhamou Y, Bochet M, Di Martino V, et al.: Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The MULTIVIR Group. Hepatology 1999, 30:1054-1058.
9. Wit FW, Weverling GJ, Weel J, et al.: Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002, 186:23-31.
10. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD: Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000, 283:74-80.
11. Kontorinis N, Dieterich D: Hepatotoxicity of antiretroviral therapy. AIDS Rev 2003, 5:36-43.
12. Kontorinis N, Dieterich DT: Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin Liver Dis 2003, 23:173-182.
13. Carr A: HIV protease inhibitor-related lipodystrophy syndrome. Clin Infect Dis 2000, 30(Suppl 2):S135-S142.
14. Pineda JA, Romero-Gomez M, Diaz-Garcia F, et al.: HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology 2005, 41:779-789.
15. Benhamou Y, Di Martino V, Bochet M, et al.: Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001, 34:283-287.
16. Qurish N, Kreuzberg C, Luchters G, et al.: Effect of antiretroviral therapy on liver-related mortality in liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003, 362:1708-1713.
17. Mehta SH, Thomas DL, Torbenson M, et al.: The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology 2005, 41:123-131.
18. Greub G LB, Lederberger B, Battegay M, et al.: Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000, 356:1800-1805.
19. Sulkowski MS, Moore RD, Mehta SH, et al.: Hepatitis C and progression of HIV disease. JAMA 2002, 288:199-206.
20. McHutchison JG, Gordon SC, Schiff ER, et al.: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998, 339:1485-1492.
21. Manns MP, McHutchison JG, Gordon SC, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001, 358:958-965.
22. McHutchison JG, Fried MW: Current therapy for hepatitis C: pegylated interferon and ribavirin. Clin Liver Dis 2003, 7:149-161.
23. Fried M, Shiffman M, Reddy R, et al.: Peginterferon alfa-2b plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-983.
24. Muir AJ, Bornstein JD, Killenberg PG: Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-hispanic whites. N Engl J Med 2004, 350:2265-2271.
25. Jeffers LJ, Cassidy W, Howell CD, et al.: Peginterferon alfa-2a (40kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004, 39:1702-1778.
26. Kaplan JE, Masur H, Holmes KK: Guidelines for preventing opportunistic infections among HIV infected persons. Morb Mortal Wkly Rep 2002, 51:1-46.
27. Soriano V, Sulkowski M, Bergin C, et al.: Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002, 16:813-828.
28. Romero M, Perez-Olmeda M, Garcia-Samaniego J, Soriano V: Management of chronic hepatitis C in patients co-infected with HIV: focus on safety considerations. Drug Saf 2004, 27:7-24.
29. Sulkowski M, Felizarta F, Smith C, et al.: Daily versus thrice-weekly interferon Alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected persons: a multicenter randomized controlled trial. J Acquir Immune Defic Syndr 2004, 35:464-472.
30. Neau D, Trimoulet P, Winnock M, et al.: Comparison of 2 regimens that include interferon-alfa-2a plus ribavirin for treatment of chronic hepatitis C in human immunodeficiency virus-coinfected patients. Clin Infect Dis 2003, 36:1564-1571.
31. Chung R, Andersen J, Volberding P, et al.: Peginterferon alfa-2a plus ribavirin vs interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-co-infected persons. N Engl J Med 2004, 351:451-459.
32. Perronne C, Carrat F, Bani-Sadr F, et al.: Final results of ANRS HC02-RIBAVIC: A randomized controlled trial of pegylated-alfa-2b plus ribavirin vs interferon-alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV co-infected patients [abstract 117LB]. Eleventh Conference on Retroviruses and Opportunistic Infections. San Fransisco, CA, February, 2004.
33. Torriani FJ, Rodriguez-Torres M, Rockstroh et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004, 351:438-450.
34. Perez-Olmeda M, Nunez M, Romero M, et al.: Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003, 17:1023-1028.
35. Levitan SA, Uriel A, Kontorinis N, Dieterich DT: Use of dronabinol for treatment of common side effects of chronic hepatitis C therapy. Gastro 2004, 126(Suppl 2):A-723.
36. Schambelan M, Benson CA, Carr A, et al.: Management of metabolic complications associated with anti-retroviral therapy for HIV-1 infection: recommendations of an international AIDS society-USA panel. J Acquir Immune Defic Syndr 2002, 31:257-275.
37. Ohnishi K, Matsuo S, Matsutani K, et al.: Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol 1996, 91:1374-1379.
38. Davis GL, Rodrigue JR: Treatment of chronic hepatitis C in active drug users. N Engl J Med 2001, 345:215-217.
39. Castera L, Zigante F, Bastie A, et al.: Incidence of interferon alfa-induced depression in patients with chronic hepatitis C. Hepatology 2002, 35:978-979.
40. Farah A: Interferon-induced depression treated with citalopram. J Clin Psychiatry 2002, 63:166-167.
41. Braun M, Vierling JM: The clinical and immunologic impact of using interferon and ribavirin in the immunosuppressed host. Liver Transpl 2003, 9:S79-S89.
42. Janssen HLA, Brouwer JF, van der Mase RC, et al.: Suicide associated with alpha-interferon therapy for chronic viral hepatitis. J Hepatol 1994, 21:241-243.
43. Fontaine H, Pol S: Side effects of interferon-alfa in treating hepatitis C virus infection. Transplant Proc 2001, 33:2327-2329.
44. Dieterich DT, Wasserman R, Brau N, et al.: Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003, 98:2491-2499.
45. McHutchison JG: Hepatitis C advances in antiviral therapy: what is accepted treatment now? J Gastroenterol Hepatol 2002, 17:431-441.
46. Mauss S, Valenti W, DePamphilis J, et al.: Risk factors for hepatic decompensation in patients with HIC/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 2004, 18:F21-F25.
47. Sulkowski MS: Anemia in the treatment of hepatitis C virus infection. Clin Infect Dis 2003, 37(Suppl 4):S315-S322.
48. Sood A RN, Russo MW, et al.: Use of granulocyte colony stimulating factor (GCSF) for interferon induced neutropenia in patients with chronic hepatitis C infection [abstract 1029]. Program and abstracts of the 52nd annual meeting of the AASLD (Dallas, TX). Alexandria: AASLD; 2001:429A.
49. Patel K, Dev A, Muir AJ, McHutchison JG: Ribavirin as maintenance therapy for hepatitis C patients: an interim peacekeeper? Hepatology 2003, 38:21-24.
50. Lafeuillade A, Hittlinger G, Chadapaud S: Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001, 357:280-281.
51. Landau A, Batisse D, Piketty C, et al.: Lack of interference between ribavirin and nucleoside analogues in HIV/HCV coinfected individuals undergoing concomitant anti-retroviral and anti-HCV combination therapy. AIDS 2000, 14:1857-1858.
52. Henessy M, Mulcahy F, Spiers P, et al.: Differential effects of combined pegylated interferon and ribavirin therapy on intracellular nucleotide triphosphate levels in HIV/HCV co-infected patients, a potential mechanism for enhanced toxicity [abstract 822]. Eleventh Conference on Retroviruses and Opportunitic Infections. San Francisco, CA, February, 2004.
53. De Franceschi L, Fattovich G. Turrini F, et al.: Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000, 31:997-1004.
54. Rendon AL, Nunez M, Romero M, et al.: Early monitoring of Ribavirin plasma concentrations may predict anemia and early virologic response in HIV/Hepatitis C virus-coinfected patients. JAIDS 2005, 39:401-405.
55. Sulkowski M, Dieterich DT, Bini E, et al.: Epoetin-alfa administered once weekly improves anemia in HIV/HCV co-infected patients treated with interferon/ribavirin therapy: a randomized controlled trial. JAIDS 2005, 39:504-506.